Utah Kratom Regulation Act Takes Effect as Manufacturers Scramble to Reformulate

TL;DR

Utah's Kratom Regulation Act went into effect May 6 after a federal judge denied an injunction, banning adulterated kratom products statewide. Meanwhile, a Philadelphia Inquirer investigation found manufacturers are already reformulating 7-OH products to sidestep pending bans in Pennsylvania and New Jersey, and a new national study reported rising kratom use among young adults.

Utah's Kratom Regulation Act went into effect on May 6 after a federal judge denied an emergency injunction, removing adulterated kratom products from shelves statewide. The ruling landed the same week a Philadelphia Inquirer investigation revealed that 7-OH manufacturers are already reformulating products to dodge pending bans in other states, and as a national study reported that kratom use among young adults continues to climb.

Utah law survives federal challenge, takes effect

U.S. District Judge Howard C. Nielson Jr. denied a preliminary injunction on May 4 that would have blocked enforcement of Utah's Kratom Regulation Act. The Global Kratom Coalition (GKC) and kratom manufacturer Botanic Tonics LLC had argued that federal law preempted the state statute.

The court disagreed. Judge Nielson held that nothing in federal law requires any particular kratom product to be sold and that states retain the police power to ban products within their borders, according to Courthouse News Service.

The law, passed by the Utah Legislature earlier this year, bans the sale of kratom products mixed with non-kratom substances and restricts high-concentration kratom extracts. Adulterated products were required to be off shelves by May 6, the day the Act took effect.

The Utah Attorney General's office described the ruling as a victory for the state's authority to regulate consumer products. The plaintiffs filed an appeal with the U.S. Court of Appeals for the Tenth Circuit on May 5, according to the Deseret News, but the law remains in effect during the appeal.

The American Kratom Association (AKA) has previously described Utah's regulatory framework as a model for the industry. The GKC and Botanic Tonics have maintained that the law overreaches by restricting products that comply with federal standards.

Manufacturers reformulate to sidestep pending 7-OH bans

While Utah's law took effect, manufacturers were already adapting to a shifting regulatory landscape in other states. A Philadelphia Inquirer investigation published May 5 found that kratom vendors at the CHAMPS trade show in Atlantic City were scrambling to offload pallets of 7-hydroxymitragynine (7-OH) products before anticipated bans in Pennsylvania and New Jersey.

Half a dozen 7-OH sales reps told the Inquirer that companies are changing their formulas to preemptively sidestep the legislation. One distributor promoted a new product called "Cori," derived from corydalis, a plant from East Asia that produces alkaloids with pain-killing properties similar to kratom's but that is not currently targeted by any proposed ban.

The investigation described a supply chain built around a small network of manufacturers that synthesize concentrated 7-OH products, often on condition of anonymity. One distributor told the Inquirer that profit margins on 7-OH products run between 200 and 300 percent: a $250,000 investment can yield roughly $1 million in revenue.

The report underscores a pattern that regulators have flagged repeatedly: as individual states move to restrict specific compounds, manufacturers reformulate around the restrictions. The FDA's scheduling recommendation for synthetic 7-OH, announced last year, has not yet resulted in a final DEA rulemaking, leaving the federal landscape unsettled.

National study: kratom use rising among young adults

A national study published in May by researchers at the University of Michigan and Texas State University found that kratom use in the United States continues to grow, with more than five million people reporting they have tried the substance at least once. The study is the first to examine kratom use patterns nationally in connection with mental health and addiction outcomes.

Adults between the ages of 21 and 34 reported the highest rates, with about 3.4 percent reporting lifetime use and roughly one percent reporting use in the past year. The study also found that more than 100,000 children between the ages of 12 and 17 reported having tried kratom, according to Medscape.

Among past-year kratom users surveyed, more than half met diagnostic criteria for a substance use disorder, and approximately 38 percent showed signs of serious psychological distress. Major depression and suicidal ideation appeared at higher rates among kratom users than in the general population, the researchers reported.

The study analyzed data from the National Survey on Drug Use and Health (NSDUH) collected from U.S. households between 2021 and 2024. Separate reporting by Medscape noted that kratom use in the U.S. has surged 65-fold over a 13-year period, based on the same survey data.

Litigation pressure builds on manufacturers

In a related development, law firm Mayer Brown published an analysis of the emerging kratom litigation landscape in early May. The report noted that plaintiffs' firms have secured significant verdicts, including a $2.5 million jury award in Washington and an $11 million default judgment in Florida.

The Mayer Brown analysis described a litigation wave accelerating through 2025 and into 2026, with wrongful death and product liability actions joined by a fraud class action in the Northern District of California and state enforcement actions in Texas targeting retailers selling products with synthetic alkaloids. Plaintiffs' theories rely heavily on failure-to-warn claims, the report noted, and punitive damages are sought in nearly every case.

One case highlighted in the analysis, Devera v. Advanced Nutrition (Wyoming) LLC, alleged a broad conspiracy among manufacturers, distributors, and the American Kratom Association to import, adulterate, and sell kratom products using opaque corporate structures to evade liability.

What to watch

The Tenth Circuit appeal of the Utah ruling will test whether states can restrict kratom products that meet federal standards, a question with implications for the growing number of state-level regulatory frameworks. Meanwhile, the FDA's scheduling recommendation for synthetic 7-OH remains with the DEA, which has not yet announced a timeline for a proposed rulemaking.

Sources